Results of Nanoform Collaborative Study to be Presented at US Drug Delivery & Formulation (DDF) Summit

Helsinki, Finland – September 11, 2025 - Nanoform Finland Plc (“Nanoform”), a leading nanoparticle medicine performance-enhancing company, today announced that key findings from two studies conducted in collaboration between Nanoform and Takeda will be presented at the 15^th American Drug Delivery & Formulation Summit (DDF) in Boston, Mass., on September 16, 2025 at 09:10 – 09:40 in Room 1.

The presentation entitled “Delivering Value for Patients Through Nanoforming in Plasma-Derived Therapies” will focus on two proof-of-concept studies conducted using Nanoform technology to enhance subcutaneous and inhaled biologic treatments.

The first study evaluated the suitability of nanoformed high-concentration biologics formulations for subcutaneous delivery. Protein concentrations above 200 mg/mL often exceed the acceptable viscosity limit for subcutaneous injection. The findings, supported by syringeability studies suggest that Nanoform’s patented biologics platform can achieve high protein concentrations in suspension formulations suitable for subcutaneous delivery.

The second non-clinical proof-of-concept study investigated nanoformed Alpha-1 antitrypsin (A1AT) in the treatment of Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder linked to lung diseases such as emphysema. Results showed that the nanoformed therapy showed promise as a targeted therapeutic approach. AAT deficiency is typically treated with weekly intravenous (IV) infusions of plasma-derived AAT, which is often inconvenient for patients. The study evaluated dry powder inhalation as an alternative route of administration for AAT replacement therapy, leveraging Nanoform’s novel solidification platform.

The 15th American Drug Delivery & Formulation Summit runs from September 15-16, 2025 (American Drug Delivery & Formulation Summit 2025) at The Westin Copley Place, Boston, Mass.

Nanoform also announced that Christopher P. Worrall, Ph.D., Vice President of Business Development, US, Nanoform, will present key case-study findings during a Solution Spotlight session at DDF.

His presentation, titled “Highly Concentrated mAb SubQ Formulations Using Nanoformed Particles: Trastuzumab,” will take place in Room 1 on Monday, September 15, from 12:15 to 12:45 p.m. EST, and will highlight the development of a highly concentrated, non-aqueous subcutaneous formulation of trastuzumab developed using Nanoform’s Bio platform.

For more information on the summit visit: nanoform.com/events. To arrange a meeting with Dr. Worrall at the DDF event, contact Christian Jones, Chief Commercial Officer, Nanoform, christian.jones@nanoform.com.